Evercore Initiates Coverage on Hemab Therapeutics (NASDAQ:COAG)

Equities researchers at Evercore started coverage on shares of Hemab Therapeutics (NASDAQ:COAG) in a note issued to investors on Tuesday. The firm set an “outperform” rating and a $50.00 price target on the stock. Evercore’s price objective would indicate a potential upside of 93.12% from the stock’s current price.

A number of other brokerages also recently weighed in on COAG. The Goldman Sachs Group began coverage on Hemab Therapeutics in a report on Tuesday. They set a “buy” rating and a $36.00 price target on the stock. Wall Street Zen upgraded Hemab Therapeutics to a “hold” rating in a report on Saturday, May 9th. Wedbush began coverage on Hemab Therapeutics in a report on Tuesday. They set an “outperform” rating and a $42.00 price target on the stock. Finally, Jefferies Financial Group began coverage on Hemab Therapeutics in a report on Tuesday. They set a “buy” rating and a $39.00 price target on the stock. Four investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Hemab Therapeutics presently has an average rating of “Buy” and a consensus price target of $41.75.

Hemab Therapeutics Price Performance

Shares of Hemab Therapeutics stock opened at $25.89 on Tuesday. Hemab Therapeutics has a 12-month low of $23.00 and a 12-month high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last announced its earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.

Insider Buying and Selling

In other news, Director Ra Capital Management, L.P. bought 2,675,000 shares of the stock in a transaction on Monday, May 4th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $48,150,000.00. Following the completion of the purchase, the director directly owned 6,149,096 shares of the company’s stock, valued at $110,683,728. This trade represents a 77.00% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders bought a total of 2,902,872 shares of company stock valued at $53,769,784 in the last quarter.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.